Yuhan Corp Preferred - Asset Resilience Ratio
Yuhan Corp Preferred (000105) has an Asset Resilience Ratio of 0.68% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of Yuhan Corp Preferred to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2025)
This chart shows how Yuhan Corp Preferred's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Yuhan Corp Preferred asset portfolio.
Liquid Assets Composition Over Time
This chart breaks down Yuhan Corp Preferred's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore 000105 long-term investments to assets to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩22.12 Billion | 0.68% |
| Total Liquid Assets | ₩22.12 Billion | 0.68% |
Asset Resilience Insights
- Limited Liquidity: Yuhan Corp Preferred maintains only 0.68% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Yuhan Corp Preferred Industry Peers by Asset Resilience Ratio
Compare Yuhan Corp Preferred's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Kamada
TA:KMDA |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 4.31% |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723 |
Drug Manufacturers - Specialty & Generic | 1.01% |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL |
Drug Manufacturers - Specialty & Generic | 5.90% |
Annual Asset Resilience Ratio for Yuhan Corp Preferred (2014–2025)
The table below shows the annual Asset Resilience Ratio data for Yuhan Corp Preferred.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.92% | ₩29.52 Billion ≈ $20.00 Million |
₩3.22 Trillion ≈ $2.18 Billion |
+0.09pp |
| 2024-12-31 | 0.82% | ₩24.23 Billion ≈ $16.42 Million |
₩2.94 Trillion ≈ $1.99 Billion |
+0.33pp |
| 2023-12-31 | 0.50% | ₩11.90 Billion ≈ $8.06 Million |
₩2.40 Trillion ≈ $1.63 Billion |
-1.72pp |
| 2022-12-31 | 2.21% | ₩54.68 Billion ≈ $37.06 Million |
₩2.47 Trillion ≈ $1.68 Billion |
-5.22pp |
| 2021-12-31 | 7.44% | ₩183.22 Billion ≈ $124.16 Million |
₩2.46 Trillion ≈ $1.67 Billion |
+3.59pp |
| 2020-12-31 | 3.85% | ₩92.11 Billion ≈ $62.42 Million |
₩2.39 Trillion ≈ $1.62 Billion |
-2.81pp |
| 2019-12-31 | 6.66% | ₩140.94 Billion ≈ $95.51 Million |
₩2.12 Trillion ≈ $1.43 Billion |
-4.10pp |
| 2018-12-31 | 10.76% | ₩233.84 Billion ≈ $158.47 Million |
₩2.17 Trillion ≈ $1.47 Billion |
-0.94pp |
| 2017-12-31 | 11.70% | ₩245.00 Billion ≈ $166.03 Million |
₩2.09 Trillion ≈ $1.42 Billion |
-0.11pp |
| 2016-12-31 | 11.81% | ₩241.58 Billion ≈ $163.71 Million |
₩2.05 Trillion ≈ $1.39 Billion |
+10.18pp |
| 2015-12-31 | 1.63% | ₩30.66 Billion ≈ $20.78 Million |
₩1.88 Trillion ≈ $1.27 Billion |
-3.19pp |
| 2014-12-31 | 4.82% | ₩77.93 Billion ≈ $52.81 Million |
₩1.62 Trillion ≈ $1.10 Billion |
-- |
About Yuhan Corp Preferred
Yuhan Corporation operates as a pharmaceutical company in South Korea and internationally. It offers manufacturing services, such as custom manufacturing; process research and development of active pharmaceutical products (APIs) and intermediates; kilo and pilot-scale production of APIs and intermediates; commercial production of APIs and intermediates; production of chemical specialties; and ana… Read more